This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krishnarao, T. V.
Right arrow Articles by Galgiani, J. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krishnarao, T. V.
Right arrow Articles by Galgiani, J. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 09 1997, 1957-1960, Vol 41, No. 9
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans

TV Krishnarao and JN Galgiani
Department of Microbiology and Immunology, University of Arizona, Tucson 85724, USA.

Two new glucan synthesis inhibitors, the echinocandin LY303366 and the pneumocandin MK-0991 (formerly L-743,872), were studied for their antifungal activities in vitro in relation to each other and in relation to the activity of the triazole fluconazole. Systematic analysis of broth macrodilution testing by varying the starting inoculum size, medium composition, medium pH, temperature of incubation, length of incubation, or selection of endpoints failed to identify significant differences in antifungal activity for either LY303366 or MK-0991 in comparison to the activity under standard test conditions specified for other antifungal agents in National Committee for Clinical Laboratory Standards (NCCLS) document M27A. Under standardized conditions, both drugs exhibited prominent activity against Candida species including Candida glabrata and Candida krusei but showed little activity against Cryptococcus neoformans. This spectrum of activity differed from that of fluconazole, which exhibited marginal activity against C. glabrata and C. krusei but prominent activity against other Candida species and C. neoformans. For individual strains, broth microdilution MICs of LY303366 and MK-0991 were similar to but frequently higher than broth macrodilution results. In contrast, fluconazole broth microdilution MICs were often lower than broth microdilution results. We conclude that the test conditions specified in NCCLS document M27A are applicable to these two new glucan synthesis inhibitors and that systematic differences between broth microdilution procedures and the broth macrodilution reference standard will need to be addressed before the two test methods can be used interchangeably.


This article has been cited by other articles:

  • Baker, L. G., Specht, C. A., Lodge, J. K. (2009). Chitinases Are Essential for Sexual Development but Not Vegetative Growth in Cryptococcus neoformans. Eukaryot Cell 8: 1692-1705 [Abstract] [Full Text]  
  • Cowen, L. E., Steinbach, W. J. (2008). Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance. Eukaryot Cell 7: 747-764 [Full Text]  
  • Dannaoui, E., Lortholary, O., Raoux, D., Bougnoux, M. E., Galeazzi, G., Lawrence, C., Moissenet, D., Poilane, I., Hoinard, D., Dromer, F., and the YEASTS Group, (2008). Comparative In Vitro Activities of Caspofungin and Micafungin, Determined Using the Method of the European Committee on Antimicrobial Susceptibility Testing, against Yeast Isolates Obtained in France in 2005-2006. Antimicrob. Agents Chemother. 52: 778-781 [Abstract] [Full Text]  
  • Baker, L. G., Specht, C. A., Donlin, M. J., Lodge, J. K. (2007). Chitosan, the Deacetylated Form of Chitin, Is Necessary for Cell Wall Integrity in Cryptococcus neoformans. Eukaryot Cell 6: 855-867 [Abstract] [Full Text]  
  • Olson, J. A., Adler-Moore, J. P., Smith, P. J., Proffitt, R. T. (2005). Treatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin. Antimicrob. Agents Chemother. 49: 4895-4902 [Abstract] [Full Text]  
  • Louie, A., Deziel, M., Liu, W., Drusano, M. F., Gumbo, T., Drusano, G. L. (2005). Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity. Antimicrob. Agents Chemother. 49: 5058-5068 [Abstract] [Full Text]  
  • Banks, I. R., Specht, C. A., Donlin, M. J., Gerik, K. J., Levitz, S. M., Lodge, J. K. (2005). A Chitin Synthase and Its Regulator Protein Are Critical for Chitosan Production and Growth of the Fungal Pathogen Cryptococcus neoformans. Eukaryot Cell 4: 1902-1912 [Abstract] [Full Text]  
  • Maligie, M. A., Selitrennikoff, C. P. (2005). Cryptococcus neoformans Resistance to Echinocandins: (1,3){beta}-Glucan Synthase Activity Is Sensitive to Echinocandins. Antimicrob. Agents Chemother. 49: 2851-2856 [Abstract] [Full Text]  
  • Ibrahim, A. S., Bowman, J. C., Avanessian, V., Brown, K., Spellberg, B., Edwards, J. E. Jr., Douglas, C. M. (2005). Caspofungin Inhibits Rhizopus oryzae 1,3-{beta}-D-Glucan Synthase, Lowers Burden in Brain Measured by Quantitative PCR, and Improves Survival at a Low but Not a High Dose during Murine Disseminated Zygomycosis. Antimicrob. Agents Chemother. 49: 721-727 [Abstract] [Full Text]  
  • Kellner, E. M., Orsborn, K. I., Siegel, E. M., Mandel, M. A., Orbach, M. J., Galgiani, J. N. (2005). Coccidioides posadasii Contains a Single 1,3-{beta}-Glucan Synthase Gene That Appears To Be Essential for Growth. Eukaryot Cell 4: 111-120 [Abstract] [Full Text]  
  • Stone, J. A., Migoya, E. M., Hickey, L., Winchell, G. A., Deutsch, P. J., Ghosh, K., Freeman, A., Bi, S., Desai, R., Dilzer, S. C., Lasseter, K. C., Kraft, W. K., Greenberg, H., Waldman, S. A. (2004). Potential for Interactions between Caspofungin and Nelfinavir or Rifampin. Antimicrob. Agents Chemother. 48: 4306-4314 [Abstract] [Full Text]  
  • Odds, F. C., Motyl, M., Andrade, R., Bille, J., Canton, E., Cuenca-Estrella, M., Davidson, A., Durussel, C., Ellis, D., Foraker, E., Fothergill, A. W., Ghannoum, M. A., Giacobbe, R. A., Gobernado, M., Handke, R., Laverdiere, M., Lee-Yang, W., Merz, W. G., Ostrosky-Zeichner, L., Peman, J., Perea, S., Perfect, J. R., Pfaller, M. A., Proia, L., Rex, J. H., Rinaldi, M. G., Rodriguez-Tudela, J.-L., Schell, W. A., Shields, C., Sutton, D. A., Verweij, P. E., Warnock, D. W. (2004). Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species. J. Clin. Microbiol. 42: 3475-3482 [Abstract] [Full Text]  
  • Odabasi, Z., Paetznick, V. L., Rodriguez, J. R., Chen, E., Ostrosky-Zeichner, L. (2004). In Vitro Activity of Anidulafungin against Selected Clinically Important Mold Isolates. Antimicrob. Agents Chemother. 48: 1912-1915 [Abstract] [Full Text]  
  • Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., Rex, J. H. (2004). Combination Antifungal Therapy. Antimicrob. Agents Chemother. 48: 693-715 [Full Text]  
  • Stone, J. A., Xu, X., Winchell, G. A., Deutsch, P. J., Pearson, P. G., Migoya, E. M., Mistry, G. C., Xi, L., Miller, A., Sandhu, P., Singh, R., deLuna, F., Dilzer, S. C., Lasseter, K. C. (2004). Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma. Antimicrob. Agents Chemother. 48: 815-823 [Abstract] [Full Text]  
  • Ohyama, T., Miyakoshi, S., Isono, F. (2004). FKS1 Mutations Responsible for Selective Resistance of Saccharomyces cerevisiae to the Novel 1,3-{beta}-Glucan Synthase Inhibitor Arborcandin C. Antimicrob. Agents Chemother. 48: 319-322 [Abstract] [Full Text]  
  • Bartizal, C., Odds, F. C. (2003). Influences of Methodological Variables on Susceptibility Testing of Caspofungin against Candida Species and Aspergillus fumigatus. Antimicrob. Agents Chemother. 47: 2100-2107 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Messer, S. A., Hollis, R. J., Jones, R. N. (2003). In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant Isolates. Antimicrob. Agents Chemother. 47: 1068-1071 [Abstract] [Full Text]  
  • Letscher-Bru, V., Herbrecht, R. (2003). Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 51: 513-521 [Abstract] [Full Text]  
  • Laverdiere, M., Restieri, C., Habel, F. (2003). Adding 2% glucose to culture media does not influence the activity of caspofungin against Candida species. J Antimicrob Chemother 51: 183-184 [Full Text]  
  • Ripeau, J.-S., Aumont, F., Belhumeur, P., Ostrosky-Zeichner, L., Rex, J. H., de Repentigny, L. (2002). Effect of the Echinocandin Caspofungin on Expression of Candida albicans Secretory Aspartyl Proteinases and Phospholipase In Vitro. Antimicrob. Agents Chemother. 46: 3096-3100 [Abstract] [Full Text]  
  • Stone, J. A., Holland, S. D., Wickersham, P. J., Sterrett, A., Schwartz, M., Bonfiglio, C., Hesney, M., Winchell, G. A., Deutsch, P. J., Greenberg, H., Hunt, T. L., Waldman, S. A. (2002). Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men. Antimicrob. Agents Chemother. 46: 739-745 [Abstract] [Full Text]  
  • Arathoon, E. G., Gotuzzo, E., Noriega, L. M., Berman, R. S., DiNubile, M. J., Sable, C. A. (2002). Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases. Antimicrob. Agents Chemother. 46: 451-457 [Abstract] [Full Text]  
  • Petraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Schaufele, R. L., Francesconi, A., Bacher, J., Avila, N. A., Walsh, T. J. (2002). Antifungal Efficacy of Caspofungin (MK-0991) in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits: Pharmacokinetics, Drug Disposition, and Relationship to Galactomannan Antigenemia. Antimicrob. Agents Chemother. 46: 12-23 [Abstract] [Full Text]  
  • Petraitis, V., Petraitiene, R., Groll, A. H., Sein, T., Schaufele, R. L., Lyman, C. A., Francesconi, A., Bacher, J., Piscitelli, S. C., Walsh, T. J. (2001). Dosage-Dependent Antifungal Efficacy of V-Echinocandin (LY303366) against Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis. Antimicrob. Agents Chemother. 45: 471-479 [Abstract] [Full Text]  
  • Arikan, S., Lozano-Chiu, M., Paetznick, V., Rex, J. H. (2001). In Vitro Susceptibility Testing Methods for Caspofungin against Aspergillus and Fusarium Isolates. Antimicrob. Agents Chemother. 45: 327-330 [Abstract] [Full Text]  
  • Chang, Y. C., Penoyer, L. A. (2000). Properties of Various RHO1 Mutant Alleles of Cryptococcus neoformans. J. Bacteriol. 182: 4987-4991 [Abstract] [Full Text]  
  • Kohler, S., Wheat, L. J., Connolly, P., Schnizlein-Bick, C., Durkin, M., Smedema, M., Goldberg, J., Brizendine, E. (2000). Comparison of the Echinocandin Caspofungin with Amphotericin B for Treatment of Histoplasmosis following Pulmonary Challenge in a Murine Model. Antimicrob. Agents Chemother. 44: 1850-1854 [Abstract] [Full Text]  
  • Chiou, C. C., Groll, A. H., Walsh, T. J. (2000). New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer. The Oncologist 5: 120-135 [Abstract] [Full Text]  
  • Clemons, K. V., Sobel, R. A., Stevens, D. A. (2000). Toxicity of LY303366, an Echinocandin Antifungal, in Mice Pretreated with Glucocorticoids. Antimicrob. Agents Chemother. 44: 378-381 [Abstract] [Full Text]  
  • Tawara, S., Ikeda, F., Maki, K., Morishita, Y., Otomo, K., Teratani, N., Goto, T., Tomishima, M., Ohki, H., Yamada, A., Kawabata, K., Takasugi, H., Sakane, K., Tanaka, H., Matsumoto, F., Kuwahara, S. (2000). In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi. Antimicrob. Agents Chemother. 44: 57-62 [Abstract] [Full Text]  
  • Chavez, M., Bernal, S., Valverde, A., Gutierrez, M. J., Quindos, G., Mazuelos, E. M. (1999). In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J Antimicrob Chemother 44: 697-700 [Abstract] [Full Text]  
  • Petraitiene, R., Petraitis, V., Groll, A. H., Candelario, M., Sein, T., Bell, A., Lyman, C. A., McMillian, C. L., Bacher, J., Walsh, T. J. (1999). Antifungal Activity of LY303366, a Novel Echinocandin B, in Experimental Disseminated Candidiasis in Rabbits. Antimicrob. Agents Chemother. 43: 2148-2155 [Abstract] [Full Text]  
  • Lozano-Chiu, M., Nelson, P. W., Paetznick, V. L., Rex, J. H. (1999). Disk Diffusion Method for Determining Susceptibilities of Candida spp. to MK-0991. J. Clin. Microbiol. 37: 1625-1627 [Abstract] [Full Text]  
  • Green, L. J., Marder, P., Mann, L. L., Chio, L.-C., Current, W. L. (1999). LY303366 Exhibits Rapid and Potent Fungicidal Activity in Flow Cytometric Assays of Yeast Viability. Antimicrob. Agents Chemother. 43: 830-835 [Abstract] [Full Text]  
  • Thompson, J. R., Douglas, C. M., Li, W., Jue, C. K., Pramanik, B., Yuan, X., Rude, T. H., Toffaletti, D. L., Perfect, J. R., Kurtz, M. (1999). A Glucan Synthase FKS1 Homolog in Cryptococcus neoformans Is Single Copy and Encodes an Essential Function. J. Bacteriol. 181: 444-453 [Abstract] [Full Text]  
  • De Lucca, A. J., Walsh, T. J. (1999). Antifungal Peptides: Novel Therapeutic Compounds against Emerging Pathogens. Antimicrob. Agents Chemother. 43: 1-11 [Full Text]  
  • Espinel-Ingroff, A. (1998). Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts. J. Clin. Microbiol. 36: 2950-2956 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»